Overview
- ViewMind Atlas identified symptomatic carriers with 100% accuracy and asymptomatic carriers with 96%, according to the study.
- Participants came from extended families in Colombia known to carry a deterministic Alzheimer’s mutation.
- The system pairs eye-tracking with Software as a Medical Device to analyze brain function during a visual short-term memory binding task.
- The AI framework used a Random Forest classifier to distinguish groups based on the presence or likelihood of Alzheimer’s.
- Researchers say the non-invasive approach may outperform traditional cognitive tests, offer a potential preclinical biomarker, and enable monitoring over time, with further validation still needed.